Revolade 25mg suspension oral(Eltrombopag)

Reference priceCNY ¥4.20Original source price: INR 350.00. Converted estimates are available by currency selection.

Brand	Revolade
Manufacturer	Novartis Pharmaceuticals
Prescription required	Yes

Description

Revolade 25mg suspension oral(Eltrombopag) is a medicine catalog record in the MediPriceHub database. Active ingredient: Eltrombopag. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Novartis Pharmaceuticals. Therapeutic category: Medicine Library > Liver and Gallbladder Diseases > Other Medicines. Pack information: 25 / 30. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

Eltrombopag tablets are thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. (1.1) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. (1.2) in combination with standard immunosuppressive therapy for the first- line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. (1.3) for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. (1.3) Limitations of Use: Eltrombopag tablets are not indicated for the treatment of patients with myelodysplastic syndrome (MDS). (1.4) Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. (1.4)

How to Use

Use Eltrombopag under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: Eltrombopag. Pack size: 25 / 30. Pack unit: box. Manufacturer: Novartis Pharmaceuticals. Origin country: Spain. Source category: Medicine Library > Liver and Gallbladder Diseases > Other Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Possible adverse effects vary by active ingredient, dose, route, treatment duration, and patient condition. Common issues may include gastrointestinal symptoms, headache, dizziness, fatigue, rash, allergic reactions, or abnormal laboratory tests. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

以上内容仅供参考。使用药品前请咨询合格的医疗专业人士。